BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 27282497)

  • 21. PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients.
    Mangone FR; Bobrovnitchaia IG; Salaorni S; Manuli E; Nagai MA
    Clinics (Sao Paulo); 2012 Nov; 67(11):1285-90. PubMed ID: 23184205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.
    Karakas B; Colak D; Kaya N; Ghebeh H; Al-Qasem A; Hendrayani F; Toulimat M; Al-Tweigeri T; Park BH; Aboussekhra A
    Cancer Biol Ther; 2013 Oct; 14(10):888-96. PubMed ID: 23982433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.
    Gasch C; Oldopp T; Mauermann O; Gorges TM; Andreas A; Coith C; Müller V; Fehm T; Janni W; Pantel K; Riethdorf S
    Mol Oncol; 2016 Oct; 10(8):1330-43. PubMed ID: 27491860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutational hotspot in exon 20 of PIK3CA in breast cancer among Singapore Chinese.
    Liang X; Lau QC; Salto-Tellez M; Putti TC; Loh M; Sukumar S
    Cancer Biol Ther; 2006 May; 5(5):544-8. PubMed ID: 16582596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deciphering the impact of somatic mutations in exon 20 and exon 9 of PIK3CA gene in breast tumors among Indian women through molecular dynamics approach.
    Sudhakar N; Priya Doss CG; Thirumal Kumar D; Chakraborty C; Anand K; Suresh M
    J Biomol Struct Dyn; 2016; 34(1):29-41. PubMed ID: 25679319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
    Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
    Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Characteristics of PIK3CA gene mutations in Her2-low breast cancer].
    Pavlenko IA; Povilaitite PE; Makarevich NS; Kaciyaev VY; Petrov AV
    Arkh Patol; 2023; 85(4):5-11. PubMed ID: 37530184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
    Dunlap J; Le C; Shukla A; Patterson J; Presnell A; Heinrich MC; Corless CL; Troxell ML
    Breast Cancer Res Treat; 2010 Apr; 120(2):409-18. PubMed ID: 19418217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel PIK3CA hotspot mutation in Isfahanian breast cancer patients.
    Gharbi S; Faghihi M; Tavassoli M
    Cancer Invest; 2011 May; 29(4):313-7. PubMed ID: 21345071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PIK3CA mutations in in situ and invasive breast carcinomas.
    Miron A; Varadi M; Carrasco D; Li H; Luongo L; Kim HJ; Park SY; Cho EY; Lewis G; Kehoe S; Iglehart JD; Dillon D; Allred DC; Macconaill L; Gelman R; Polyak K
    Cancer Res; 2010 Jul; 70(14):5674-8. PubMed ID: 20551053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
    Sabine VS; Crozier C; Brookes CL; Drake C; Piper T; van de Velde CJ; Hasenburg A; Kieback DG; Markopoulos C; Dirix L; Seynaeve C; Rea DW; Bartlett JM
    J Clin Oncol; 2014 Sep; 32(27):2951-8. PubMed ID: 25071141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The High Frequency of PIK3CA Mutations in Iranian Breast Cancer Patients.
    Azizi Tabesh G; Izadi P; Fereidooni F; Emami Razavi AN; Tavakkoly Bazzaz J
    Cancer Invest; 2017 Jan; 35(1):36-42. PubMed ID: 27901576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiplexed assays for detection of mutations in PIK3CA.
    Board RE; Thelwell NJ; Ravetto PF; Little S; Ranson M; Dive C; Hughes A; Whitcombe D
    Clin Chem; 2008 Apr; 54(4):757-60. PubMed ID: 18375489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
    Saal LH; Holm K; Maurer M; Memeo L; Su T; Wang X; Yu JS; Malmström PO; Mansukhani M; Enoksson J; Hibshoosh H; Borg A; Parsons R
    Cancer Res; 2005 Apr; 65(7):2554-9. PubMed ID: 15805248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR
    Moynahan ME; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Ringeisen F; Hortobagyi GN; Baselga J; Chandarlapaty S
    Br J Cancer; 2017 Mar; 116(6):726-730. PubMed ID: 28183140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.
    Mori R; Ishiguro H; Kimura M; Mitsui A; Sasaki H; Tomoda K; Mori Y; Ogawa R; Katada T; Kawano O; Harada K; Fujii Y; Kuwabara Y
    J Surg Res; 2008 Apr; 145(2):320-6. PubMed ID: 18262558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients.
    Deng L; Zhu X; Sun Y; Wang J; Zhong X; Li J; Hu M; Zheng H
    Cancer Res Treat; 2019 Jan; 51(1):128-140. PubMed ID: 29540052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of PIK3CA mutations in breast cancer subtypes.
    Arsenic R; Lehmann A; Budczies J; Koch I; Prinzler J; Kleine-Tebbe A; Schewe C; Loibl S; Dietel M; Denkert C
    Appl Immunohistochem Mol Morphol; 2014 Jan; 22(1):50-6. PubMed ID: 24471188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.